Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Up – Still a Buy?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $11.34, but opened at $11.97. Bayer Aktiengesellschaft shares last traded at $11.96, with a volume of 152,149 shares.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on BAYRY shares. Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Zacks Research downgraded shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Finally, JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Bayer Aktiengesellschaft presently has an average rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

The stock’s 50-day moving average price is $9.70 and its 200 day moving average price is $8.60. The company has a quick ratio of 0.71, a current ratio of 1.14 and a debt-to-equity ratio of 1.10. The firm has a market cap of $45.35 billion, a price-to-earnings ratio of -134.49, a price-to-earnings-growth ratio of 5.70 and a beta of 0.66.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.